Colinz Labs

When is the next results date for Colinz Labs?

No Upcoming Board Meetings

Who are in the management team of Colinz Labs?

As of March 2023, the management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director). They are responsible for the company's governance and operations.

As of March 2023, the management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Colinz Labs do?

Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures various pharmaceutical formulations. As of March 2025, it reported net sales of 1 Cr and a market capitalization of Rs 29 Cr.

Overview: <BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures a wide variety of pharmaceutical formulations.<BR><BR>History: <BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it began its manufacturing and marketing activities. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: 5.35% <BR>Price to Book: 3.06<BR><BR>Contact Details: <BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Has Colinz Labs declared dividend?

No Dividend History Available

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Dr Reddy's Labs show excellent management and growth, Colinz Labs has below-average growth and management risk, with a 1-year return of 66.49%.

Peers: The peers of Colinz Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Zenith Health, Ishita Drugs, Chemo Pharma Lab, Phaarmasia, and Desh Rakshak.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Colinz Labs, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Colinz Labs, Divi's Lab., Torrent Pharma, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is present at Colinz Labs, Torrent Pharma, and Zenith Health, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the lowest is Phaarmasia at -24.74%. Colinz Labs has a 1-year return of 66.49%, which is significantly higher than Phaarmasia but lower than Desh Rakshak. Additionally, peers with negative six-month returns include Zenith Health, Phaarmasia, and Chemo Pharma Lab.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

How big is Colinz Labs?

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, with recent net sales of 6.53 Cr and a net profit of 0.50 Cr. Shareholder's funds are 8.95 Cr and total assets amount to 11.36 Cr.

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 6.53 Cr and a Net Profit of 0.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8.95 Cr and Total Assets of 11.36 Cr.

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

Are Colinz Laboratories Ltd latest results good or bad?

Colinz Laboratories Ltd's latest Q3 FY26 results are largely negative, with a 2.88% increase in revenue to ₹1.43 crores but a significant 42.86% drop in net profit to ₹0.08 crores, indicating challenges in profitability and operational efficiency. The declining PAT margin raises concerns about the company's long-term viability.

Colinz Laboratories Ltd's latest results for Q3 FY26 present a mixed picture, but overall, they lean towards the negative side. While the company reported a slight increase in revenue, with net sales rising by 2.88% quarter-on-quarter to ₹1.43 crores, its net profit fell significantly by 42.86% to ₹0.08 crores. This indicates a troubling decline in profitability despite stable revenue.<BR><BR>Moreover, the company's PAT margin has dropped sharply from 10.07% in the previous quarter to 5.59%, reflecting deteriorating operational efficiency. The operating margin did improve slightly to 6.99%, but this is still below the levels achieved in previous quarters. <BR><BR>The overall financial performance suggests that Colinz Laboratories is struggling with significant challenges, including weak capital efficiency and persistent margin volatility. The company's inability to achieve consistent growth and maintain profitability raises concerns about its long-term viability. Given these factors, the latest results can be considered bad, highlighting fundamental issues that need to be addressed for any potential recovery.

Should I buy, sell or hold Colinz Laboratories Ltd?

Which are the latest news on Colinz Labs?

Why is Colinz Laboratories Ltd falling/rising?

As of 09-Feb, Colinz Laboratories Ltd's stock price is Rs 60.33, down 4.99% and has fallen for six consecutive days, totaling a 24.61% decline. Despite a year-to-date increase of 12.49%, recent trends show significant underperformance compared to its sector and the broader market.

As of 09-Feb, Colinz Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 60.33, which reflects a change of -3.17 (-4.99%). The stock has been underperforming significantly, having fallen for the last six consecutive days, resulting in a total decline of -24.61% during this period. Additionally, the stock's performance today has underperformed its sector by -6.57%.<BR><BR>In terms of broader performance metrics, over the past week, the stock has decreased by -20.64%, while the Sensex has increased by +2.94%. Despite a positive performance over longer periods, such as a +12.49% increase year-to-date and a +456.04% increase over five years, the recent trend indicates a sharp downturn.<BR><BR>Investor participation has seen a rise, with delivery volume increasing by 266.65% against the five-day average, suggesting some interest in the stock despite its falling price. However, the stock's current price is below the 5-day moving averages, indicating a short-term bearish trend. Overall, the combination of consecutive price declines, underperformance relative to the sector, and recent trading activity contributes to the current downward movement in Colinz Laboratories Ltd's stock price.